Novel Therapeutic for Treating or Preventing Lung Disorders Using Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (Case 2273)

Principal Investigator:


Monique E. De Paepe, MD
Professor of Pathology and Laboratory Medicine
Brown University
Providence, RI


Brief Description:


The technology uses umbilical cord tissue-derived mesenchymal stem cells as a therapeutic for treating or preventing lung disorders in patients of all ages, but especially in premature infants. The incidence of premature delivery is between 11-12% in the United States. Premature infants with structurally immature lungs born between 23 and 28 weeks gestation are at risk for bronchopulmonary dysplasia (BPD) or chronic lung disease of the preterm newborn, a complex condition associated with high perinatal morbidity and mortality. Long-term complications of individuals suffering from BPD include asthma, emphysema, and poor neurodevelopmental outcome. There is a major unmet need to find a treatment for BPD and other lung disorders.


The technology occupies a unique space within the global respiratory disorders market which was estimated to be worth $28.1 billion USD in 2015. The global respiratory disorders market is forecast to grow to $46.6 billion USD by 2022 at a CAGR of 7.5%. Over the past decade, the treatment of respiratory disorders has continued to advance, as has the importance for developing novel and targeted therapies. The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies which treat symptoms rather than causes of disease. More traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder therapeutic pipeline, but the pipeline also contains promising targeted biologic therapies. Current key players in the market include AstraZeneca, Boehringer, GSK, Merck, Roche, Novartis, and others. As a therapeutic which directly treats causes of lung disorders, such as BPD, and may thereby prevent further lung disorder symptoms from occurring, the technology has the power to carve out a unique niche within the biologic therapies space in the greater global respiratory disorders market.


Overall, the technology addresses the major unmet need of serving as a potential treatment for BPD and other lung disorders. The technology improves or restores the function of injured lungs using umbilical cord tissue-derived mesenchymal stem cells. When administered to a patient, the technology may also prevent lung disorders and lung disorder complications. The technology can be administered to a patient of any age, such as a newborn, infant, child, or adult. Potential customers include pharmaceutical and biotechnology companies, hospitals, veterinarians, and biomedical researchers. The technology has the potential to carve out a unique niche in the global respiratory disorders market and may have therapeutic potential for treating or even preventing a variety of lung disorders, including but not limited to BPD, COPD, and emphysema.




U.S. patent application 15/036,618 is pending.


Patent Information:
For Information, Contact:
Margaret Shabashevich,
Manager of Operations
Technology Ventures Office
Brown University
Monique DePaepe
© 2017. All Rights Reserved. Powered by Inteum